California-based pharmaceutical giant Gilead Sciences has announced that a five-day course of its antiviral drug Remdesivir — shown in tests to effectively fight COVID-19 — will cost $3,120 to Americans with health insurance and $2,340 to those on Medicaid. Yet research published in April calculated that the drug could be produced at a profit for
吉利德公司决定对COVID药物收取3000美元的费用,因此产生了几分钱的生产费用,公众对此表示强烈抗议
更糟的是,伦地昔韦是一种药物,“其开发成本在很大程度上由中国,政府和卫生部,世界卫生组织和美国政府等独立捐助者支付的。”